View Item 

Show simple item record

PRAME expression in spindle cell melanoma, malignant peripheral nerve sheath tumour, and other cutaneous sarcomatoid neoplasms: a comparative analysis

dc.contributor.authorHrycaj, Steven M
dc.contributor.authorSzczepanski, Julianne M
dc.contributor.authorZhao, Lili
dc.contributor.authorSiddiqui, Javed
dc.contributor.authorThomas, Dafydd G
dc.contributor.authorLucas, David R
dc.contributor.authorPatel, Rajiv M
dc.contributor.authorHarms, Paul W
dc.contributor.authorBresler, Scott C
dc.contributor.authorChan, May P
dc.date.accessioned2022-12-05T16:42:13Z
dc.date.available2024-01-05 11:42:10en
dc.date.available2022-12-05T16:42:13Z
dc.date.issued2022-12
dc.identifier.citationHrycaj, Steven M; Szczepanski, Julianne M; Zhao, Lili; Siddiqui, Javed; Thomas, Dafydd G; Lucas, David R; Patel, Rajiv M; Harms, Paul W; Bresler, Scott C; Chan, May P (2022). "PRAME expression in spindle cell melanoma, malignant peripheral nerve sheath tumour, and other cutaneous sarcomatoid neoplasms: a comparative analysis." Histopathology (6): 818-825.
dc.identifier.issn0309-0167
dc.identifier.issn1365-2559
dc.identifier.urihttps://hdl.handle.net/2027.42/175248
dc.publisherWiley Periodicals, Inc.
dc.subject.othermelanoma
dc.subject.otherPRAME
dc.subject.othersarcomatoid
dc.subject.othermalignant peripheral nerve sheath tumour
dc.titlePRAME expression in spindle cell melanoma, malignant peripheral nerve sheath tumour, and other cutaneous sarcomatoid neoplasms: a comparative analysis
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelMicrobiology and Immunology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175248/1/his14797_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/175248/2/his14797.pdf
dc.identifier.doi10.1111/his.14797
dc.identifier.sourceHistopathology
dc.identifier.citedreferenceAgaimy A, Stoehr R, Hornung A et al. Dedifferentiated and undifferentiated melanomas: report of 35 new cases with literature review and proposal of diagnostic criteria. Am. J. Surg. Pathol. 2021; 45; 240 – 254.
dc.identifier.citedreferenceWeissinger SE, Keil P, Silvers DN et al. A diagnostic algorithm to distinguish desmoplastic from spindle cell melanoma. Mod. Pathol. 2014; 27; 524 – 534.
dc.identifier.citedreferenceKaramchandani JR, Nielsen TO, van de Rijn M, West RB. Sox10 and s100 in the diagnosis of soft-tissue neoplasms. Appl. Immunohistochem. Mol. Morphol. 2012; 20; 445 – 450.
dc.identifier.citedreferenceMiettinen MM, Antonescu CR, Fletcher CDM et al. Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview. Hum. Pathol. 2017; 67; 1 – 10.
dc.identifier.citedreferenceNonaka D, Chiriboga L, Rubin BP. Sox10: a pan-schwannian and melanocytic marker. Am. J. Surg. Pathol. 2008; 32; 1291 – 1298.
dc.identifier.citedreferenceSchaefer IM, Fletcher CD, Hornick JL. Loss of h3k27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod. Pathol. 2016; 29; 4 – 13.
dc.identifier.citedreferenceMito JK, Qian X, Doyle LA, Hornick JL, Jo VY. Role of histone h3k27 trimethylation loss as a marker for malignant peripheral nerve sheath tumor in fine-needle aspiration and small biopsy specimens. Am. J. Clin. Pathol. 2017; 148; 179 – 189.
dc.identifier.citedreferencePrieto-Granada CN, Wiesner T, Messina JL, Jungbluth AA, Chi P, Antonescu CR. Loss of h3k27me3 expression is a highly sensitive marker for sporadic and radiation-induced mpnst. Am. J. Surg. Pathol. 2016; 40; 479 – 489.
dc.identifier.citedreferenceDavis LE, Shalin SC, Tackett AJ. Utility of histone h3k27me3 and h4k20me as diagnostic indicators of melanoma. Melanoma Res. 2020; 30; 159 – 165.
dc.identifier.citedreferenceThangaiah JJ, Westling BE, Roden AC et al. Loss of dimethylated h3k27 (h3k27me2) expression is not a specific marker of malignant peripheral nerve sheath tumor (mpnst): an immunohistochemical study of 137 cases, with emphasis on mpnst and melanocytic tumors. Ann. Diagn. Pathol. 2022; 59; 151967.
dc.identifier.citedreferenceMarchione DM, Lisby A, Viaene AN et al. Histone h3k27 dimethyl loss is highly specific for malignant peripheral nerve sheath tumor and distinguishes true prc2 loss from isolated h3k27 trimethyl loss. Mod. Pathol. 2019; 32; 1434 – 1446.
dc.identifier.citedreferenceSekoranja D, Hawlina G, Pizem J. Prame expression in melanocytic lesions of the conjunctiva. Histopathology 2021; 79; 989 – 996.
dc.identifier.citedreferenceAlbertsmeier M, Altendorf-Hofmann A, Lindner LH et al. Cancer testis antigens and immunotherapy: expression of prame is associated with prognosis in soft tissue sarcoma. Cancers (Basel) 2020; 12; 3612.
dc.identifier.citedreferenceAgaimy A, Specht K, Stoehr R et al. Metastatic malignant melanoma with complete loss of differentiation markers (undifferentiated/dedifferentiated melanoma): analysis of 14 patients emphasizing phenotypic plasticity and the value of molecular testing as surrogate diagnostic marker. Am. J. Surg. Pathol. 2016; 40; 181 – 191.
dc.identifier.citedreferenceFerreira I, Arends MJ, van der Weyden L, Adams DJ, Brenn T. Primary de-differentiated, trans-differentiated and undifferentiated melanomas: overview of the clinicopathological, immunohistochemical and molecular spectrum. Histopathology 2022; 80; 135 – 149.
dc.identifier.citedreferenceBusam KJ. Desmoplastic melanoma. Surg. Pathol. Clin. 2009; 2; 511 – 520.
dc.identifier.citedreferenceErstine EM, Tetzlaff MT, Ko JS, Prieto VG, Cheah AL, Billings SD. Living on the edge: diagnosing sarcomatoid melanoma using histopathologic cues at the edge of a dedifferentiated tumor: a report of 2 cases and review of the literature. Am. J. Dermatopathol. 2017; 39; 593 – 598.
dc.identifier.citedreferenceMcBride JD, McAfee JL, Piliang M et al. Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms. J. Cutan. Pathol. 2021; 49; 220 – 230.
dc.identifier.citedreferenceHu J, Cai X, Lv JJ et al. Preferentially expressed antigen in melanoma immunohistochemistry as an adjunct for differential diagnosis in acral lentiginous melanoma and acral nevi. Hum. Pathol. 2021; 120; 9 – 17.
dc.identifier.citedreferenceMiettinen M. Immunohistochemistry of soft tissue tumours - review with emphasis on 10 markers. Histopathology 2014; 64; 101 – 118.
dc.identifier.citedreferenceElsensohn A, Hanson J, Ferringer T. Preferentially expressed antigen in melanoma expression in nonmelanoma skin cancers and melanocytes in surrounding skin. J. Cutan. Pathol. 2021; 48; 1150 – 1155.
dc.identifier.citedreferenceAlrabadi N, Gibson N, Curless K et al. Detection of driver mutations in braf can aid in diagnosis and early treatment of dedifferentiated metastatic melanoma. Mod. Pathol. 2019; 32; 330 – 337.
dc.identifier.citedreferenceHelbig D, Ihle MA, Putz K et al. Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas. Oncotarget 2016; 7; 21763 – 21774.
dc.identifier.citedreferenceMiller TI, Zoumberos NA, Johnson B et al. A genomic survey of sarcomas on sun-exposed skin reveals distinctive candidate drivers and potentially targetable mutations. Hum. Pathol. 2020; 102; 60 – 69.
dc.identifier.citedreferenceIura K, Kohashi K, Hotokebuchi Y et al. Cancer-testis antigens prame and ny-eso-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma. J. Pathol. Clin. Res. 2015; 1; 144 – 159.
dc.identifier.citedreferenceSzczepanski MJ, DeLeo AB, Luczak M et al. Prame expression in head and neck cancer correlates with markers of poor prognosis and might help in selecting candidates for retinoid chemoprevention in pre-malignant lesions. Oral Oncol. 2013; 49; 144 – 151.
dc.identifier.citedreferenceWu X, Wang W, Lai X et al. Cd24 and prame are novel grading and prognostic indicators for pineal parenchymal tumors of intermediate differentiation. Am. J. Surg. Pathol. 2020; 44; 11 – 20.
dc.identifier.citedreferenceCadwell CR, Yuksek GE, Hirbe AC et al. Preferentially expressed antigen in melanoma (prame) expression in malignant, but not benign, peripheral nerve sheath tumors. J. Neuropathol. Exp. Neurol. 2021; 80; 384 – 386.
dc.identifier.citedreferenceIkeda H, Lethe B, Lehmann F et al. Characterization of an antigen that is recognized on a melanoma showing partial hla loss by ctl expressing an nk inhibitory receptor. Immunity 1997; 6; 199 – 208.
dc.identifier.citedreferenceEpping MT, Hart AA, Glas AM, Krijgsman O, Bernards R. Prame expression and clinical outcome of breast cancer. Br. J. Cancer 2008; 99; 398 – 403.
dc.identifier.citedreferenceField MG, Decatur CL, Kurtenbach S et al. Prame as an independent biomarker for metastasis in uveal melanoma. Clin. Cancer Res. 2016; 22; 1234 – 1242.
dc.identifier.citedreferenceHemminger JA, Toland AE, Scharschmidt TJ, Mayerson JL, Guttridge DC, Iwenofu OH. Expression of cancer-testis antigens magea1, magea3, acrbp, prame, ssx2, and ctag2 in myxoid and round cell liposarcoma. Mod. Pathol. 2014; 27; 1238 – 1245.
dc.identifier.citedreferenceLezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ. Prame expression in melanocytic tumors. Am. J. Surg. Pathol. 2018; 42; 1456 – 1465.
dc.identifier.citedreferenceNeumann E, Engelsberg A, Decker J et al. Heterogeneous expression of the tumor-associated antigens rage-1, prame, and glycoprotein 75 in human renal cell carcinoma: Candidates for t-cell-based immunotherapies? Cancer Res. 1998; 58; 4090 – 4095.
dc.identifier.citedreferenceOberthuer A, Hero B, Spitz R, Berthold F, Fischer M. The tumor-associated antigen prame is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin. Cancer Res. 2004; 10; 4307 – 4313.
dc.identifier.citedreferencePujol JL, De Pas T, Rittmeyer A et al. Safety and immunogenicity of the prame cancer immunotherapeutic in patients with resected non-small cell lung cancer: a phase i dose escalation study. J. Thorac. Oncol. 2016; 11; 2208 – 2217.
dc.identifier.citedreferenceZhang W, Barger CJ, Eng KH et al. Prame expression and promoter hypomethylation in epithelial ovarian cancer. Oncotarget 2016; 7; 45352 – 45369.
dc.identifier.citedreferenceLezcano C, Pulitzer M, Moy AP, Hollmann TJ, Jungbluth AA, Busam KJ. Immunohistochemistry for prame in the distinction of nodal nevi from metastatic melanoma. Am. J. Surg. Pathol. 2020; 44; 503 – 508.
dc.identifier.citedreferenceRaghavan SS, Wang JY, Toland A et al. Diffuse prame expression is highly specific for malignant melanoma in the distinction from clear cell sarcoma. J. Cutan. Pathol. 2020; 47; 1226 – 1228.
dc.identifier.citedreferenceKline N, Menge TD, Hrycaj SM et al. Prame expression in challenging dermal melanocytic neoplasms and soft tissue tumors with melanocytic differentiation. Am. J. Dermatopathol. 2022; 44; 404 – 410.
dc.identifier.citedreferenceLe Guellec S, Macagno N, Velasco V et al. Loss of h3k27 trimethylation is not suitable for distinguishing malignant peripheral nerve sheath tumor from melanoma: a study of 387 cases including mimicking lesions. Mod. Pathol. 2017; 30; 1677 – 1687.
dc.identifier.citedreferenceThway K, Fisher C. Malignant peripheral nerve sheath tumor: pathology and genetics. Ann. Diagn. Pathol. 2014; 18; 109 – 116.
dc.identifier.citedreferenceBiglow LR, Cuda J, Dotson J. A rare case of epithelioid malignant peripheral nerve sheath tumor mimicking malignant melanoma. Cureus 2021; 13; e13424.
dc.identifier.citedreferenceGaspard M, Lamant L, Tournier E et al. Evaluation of eight melanocytic and neural crest-associated markers in a well-characterised series of 124 malignant peripheral nerve sheath tumours (mpnst): useful to distinguish mpnst from melanoma? Histopathology 2018; 73; 969 – 982.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
his14797_am.pdf
Size:
12.22MB
Format:
PDF
View/Open
Name:
his14797.pdf
Size:
1.182MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.